Emergent BioSolutions (EBS) to Release Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Emergent BioSolutions to post earnings of $0.49 per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The business had revenue of $254.70 million during the quarter, compared to analyst estimates of $199.47 million. During the same quarter last year, the company posted ($1.06) EPS. On average, analysts expect Emergent BioSolutions to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $9.12 on Monday. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company’s 50 day moving average is $8.33 and its 200 day moving average is $7.54. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The company has a market cap of $482.54 million, a PE ratio of -0.81 and a beta of 1.57.

Analyst Upgrades and Downgrades

EBS has been the topic of several research reports. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.